SYGNIS Capital Increase oversubscribed at final Closing

SYGNIS Capital Increase oversubscribed at final Closing

…players in drug development, molecular diagnostics and personalized healthcare. The contemplated transaction in our view is in the best interest of the Company and its shareholders as it provides the Company…

2
Like
Save

Comments

Write a comment

*